Tasigna's Atherosclerosis Risk Is Well-Documented By Researchers For Peer-Reviewed Medical Publications

Novartis has buried critical Tasigna atherosclerosis warnings deep in its website where it is unlikely to draw much attention

Wednesday, May 8, 2019 - Independent objective, peer-reviewed medical journals have reported that anti-cancer chemotherapy drug Tasigna carries severe and life-threatening side effects. Much has been written by Leukemia, the authoritative source on cancer of the blood, and republished by the National Institute of Health (NIH). "Two papers in Leukemia recently reported the prevalence of peripheral artery occlusive disease (PAOD) in tyrosine kinase inhibitor (TKI)-treated patients with chronic myeloid leukemia (CML)." Tasigna is the leading TKI drug that is given as a last resort to CML patients. Studies published in the American Journal of Hematology in 2016 confirmed the growing concern that Tasigna could lead to atherosclerosis and peripheral artery disease when their study of post-market clinical data concluded that 25% of Tasigna patients experienced a "vascular event" and more than half of them developed full-blown peripheral arterial disease. The American Health Association Journal wrote about the "increased cardiovascular risk factors and adverse events related to atherosclerosis" from using Imatinib (Tasigna), a tyrosine kinase inhibitor. Swiss pharmaceutical conglomerate Novartis AG became aware of the Tasigna atherosclerosis link in 2011 and alerted Health Canada, Canada's FDA, in an article entitled "TASIGNA (nilotinib) - Possible Risk of Developing Atherosclerosis-Related Conditions - For the Public." Although Novartis chose to warn Canada, ad much has been written to document Tasigna's role in causing atherosclerosis, no clear warning ever made it to doctors in the US to be cautious when prescribing Tasigna. Tasigna Atherosclerosis lawyers can advise families and individuals harmed by Tasigna drug before filing a claim.

As a result of these studies and the Health Canada warning, Novartis was forced to update the Tasigna warning label to include sudden death and amputation risk as possible side effects from taking the drug. Doctors that prescribe Tasigna are advised to monitor their patient's heart condition by performing an ECG before, during and for months after giving a patient Tasigna to look for changes in heart rhythm. Tasigna warns that sudden death can occur in patients that have a history of heart disease. The warning is extended to include up to 6% of Tasigna patients developing atherosclerosis "cardiovascular events included peripheral arterial occlusive disease (1.4% and 1.1% at 300 mg and 400 mg TASIGNA twice daily, respectively), ischaemic heart disease (2.2% and 6.1% at 300 mg and 400 mg TASIGNA twice daily, respectively) and ischaemic cerebrovascular events (1.1% and 2.2% at 300 mg and 400 mg TASIGNA twice daily, respectively)."

Atherosclerosis is the most deadly of all of Tasigna's side effects and leads to plaque building up within the arteries causing them to narrow and restrict the flow of blood. Tasigna atherosclerosis differs from dietary atherosclerosis in that the latter can take years to develop whereas Tasigna induced atherosclerosis happens rapidly and irreversibly and causes blockages leading to strokes, heart attacks and tissue death in the extremities that would require amputation

Cancer patients in the United States have never been officially warned of the risks of developing atherosclerosis from using Tasigna.

More Recent Tasigna Atherosclerosis Lawsuit News:

No-Cost, No-Obligation Tasigna Lawsuit Case Review If You or a Loved One Suffered from Tasigna Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.